Literature DB >> 19528365

Regulation of renovascular adenosine 3',5'-cyclic monophosphate in spontaneously hypertensive rats.

Edwin K Jackson1, Zaichuan Mi.   

Abstract

This study tested the hypothesis that regulation of 3',5'-cAMP levels in the kidney vasculature is abnormal in spontaneously hypertensive rats. In isolated, perfused kidneys from adult rats (16 weeks of age), isoproterenol similarly increased renal venous 3',5'-cAMP secretion from kidneys of hypertensive versus normotensive Wistar-Kyoto rats. However, a broad-spectrum phosphodiesterase inhibitor (isobutyl-1-methylxanthine) augmented isoproterenol (3 mumol/L)-induced increases in renal venous 3',5'-cAMP secretion more so in kidneys from adult hypertensive versus age-matched normotensive rats (31-fold and 5-fold, respectively; P<0.0001). In contrast to isoproterenol, broad-spectrum phosphodiesterase inhibition augmented forskolin-induced increases in renal venous 3',5'-cAMP secretion similarly in kidneys from adult hypertensive versus age-matched normotensive rats. In kidneys from adults of both strains, the effects of isobutyl-1-methylxanthine on isoproterenol-induced 3',5'-cAMP responses were mimicked by the inhibition of phosphodiesterase 4 (RO 20-1724) but not by the inhibition of phosphodiesterase 1 (3,8-methoxymethyl-3-isobutyl-1-methylxanthine) or phosphodiesterase 3 (milrinone). In kidneys from young (5 weeks of age), adult, and old (39 weeks of age) rats, RO 20-1724 augmented isoproterenol-induced renal 3',5'-cAMP secretion more so in kidneys from hypertensive rats. In adult hypertensive rats, arterial blood pressure and renal vascular resistance were elevated compared with age-matched normotensive rats, and intravenous infusions of RO 20-1724 reduced blood pressure and renal vascular resistance in hypertensive rats but had little effect on these variables in normotensive rats. We conclude that, in the renal vasculature of spontaneously hypertensive rats (young, adult, and old), there is increased activity of a compartment of phosphodiesterase 4. Selective inhibition of renal vascular phosphodiesterase 4 may represent a new strategy for improving renal hemodynamics in genetic hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528365      PMCID: PMC2755265          DOI: 10.1161/HYPERTENSIONAHA.109.130542

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

Review 1.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

2.  Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.

Authors:  J A Carcillo; W A Herzer; Z Mi; N J Thomas; E K Jackson
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

Review 3.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

4.  Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.

Authors:  D P Begany; J A Carcillo; W A Herzer; Z Mi; E K Jackson
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

5.  Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells.

Authors:  R K Dubey; D G Gillespie; E K Jackson
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

6.  Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension.

Authors:  C Chatziantoniou; X Ruan; W J Arendshorst
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  The inhibitory effect of angiotensin II on stimulus-induced release of cAMP is augmented in the genetically hypertensive rat kidney.

Authors:  S J Vyas; Z Mi; E K Jackson
Journal:  J Pharmacol Exp Ther       Date:  1996-10       Impact factor: 4.030

8.  Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats.

Authors:  R Mokkapatti; S J Vyas; G G Romero; Z Mi; T Inoue; R K Dubey; D G Gillespie; A K Stout; E K Jackson
Journal:  J Pharmacol Exp Ther       Date:  1998-10       Impact factor: 4.030

9.  Interactions of cAMP-mediated vasodilators with angiotensin II in rat kidney during hypertension.

Authors:  C Chatziantoniou; X Ruan; W J Arendshorst
Journal:  Am J Physiol       Date:  1993-12

10.  Angiotensin and thromboxane in genetically hypertensive rats: renal blood flow and receptor studies.

Authors:  C Chatziantoniou; W J Arendshorst
Journal:  Am J Physiol       Date:  1991-08
View more
  3 in total

1.  Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats.

Authors:  Dongmei Cheng; Jin Ren; Delbert G Gillespie; Zaichuan Mi; Edwin K Jackson
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

2.  Role of 2',3'-cyclic nucleotide 3'-phosphodiesterase in the renal 2',3'-cAMP-adenosine pathway.

Authors:  Edwin K Jackson; Delbert G Gillespie; Zaichuan Mi; Dongmei Cheng; Rashmi Bansal; Keri Janesko-Feldman; Patrick M Kochanek
Journal:  Am J Physiol Renal Physiol       Date:  2014-05-07

3.  Extracellular 2',3'-cAMP is a source of adenosine.

Authors:  Edwin K Jackson; Jin Ren; Zaichuan Mi
Journal:  J Biol Chem       Date:  2009-10-01       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.